We are regularly recognized as leaders in the biotechnology industry. We also receive recognition and awards for our overall performance as a company, our dynamic workplace culture, our contributions to the community and our patient advocacy. Here are some of our most recent achievements.
In June 2016, Computerworld ranked Genentech No. 3 among large companies on its list of the “100 Best Places to Work in IT.” This is Genentech’s eighth year on the list. Genentech was also ranked No. 1 overall for employee benefits.
To select and rank the top workplaces for IT professionals, Computerworld surveyed more than 450 companies about compensation, promotions, turnover, professional development opportunities, workplace culture, employee benefits and diversity among their IT staff. In a separate employee survey, the IT staff at each company were asked to rate their satisfaction with several key aspects of their jobs and workplaces.
When scoring survey responses, Computerworld weighted each company’s results based on employee ratings of how important each workplace aspect or benefit was to them. Approximately half of the total scoring was based on employee responses, with the remainder based on the survey of the company’s benefits and other programs.
In April 2016, FORTUNE magazine ranked Genentech No. 11 on its inaugural list of the “Top 50 Workplaces for Giving Back.” The list recognizes companies that provide their employees with the opportunity to make a positive impact both on and off the job.
To identify the honorees, FORTUNE and Great Place to Work surveyed more than 240,000 randomly-selected employees and collected program information from nearly 600 organizations. Two-thirds of each company’s score is based on employees’ ratings of whether they feel they are able to make a difference in their communities, and the degree to which they feel they have the support of their organization to give back. The remaining third of each company’s score is based on the generosity of its community-oriented programs, relative to its size and revenue.
In April 2016, DiversityInc named Genentech to its list of the “Top 50 Companies for Diversity,” as well as its list of the “Top 12 Companies for Employee Resource Groups.”
DiversityInc’s Top 50 list ranks companies on their diversity management initiatives. The rankings are based on corporate survey submissions from more than 1,600 companies. Companies are evaluated within the context of their own industries on four equally weighted areas: supplier diversity, talent pipeline, equitable talent development and CEO/senior leadership commitment.
In January 2016, Joe Arron, M.D, Ph.D., director of Immunology Discovery, was elected to membership in the American Society of Clinical Investigation (ASCI) for his scientific accomplishments that have changed the therapeutic paradigm for the treatment of asthma and, potentially, other pulmonary diseases.
Election to membership in the ASCI recognizes significant research contributions that extend biological understanding and improve treatment of human diseases. Founded in 1908, the ASCI is one of the nation’s oldest and most respected medical honor societies.
Previous elections include Timothy W. Behrens, Ph.D., senior director, OMNI Human Genetics (2000), Andrew C. Chan, M.D., Ph.D., senior vice president, Research Biology (1999), Teresa Wright, principal medical director, Immunology (1998), Vishva M. Dixit, M.D., vice president, Physiological Chemistry (1996), John B. Lowe, Ph.D., senior director, Pathology (1994), and Eric Brown, M.D., vice president, Immunology and Infectious Diseases (1987).
In March 2016, FORTUNE magazine named Genentech one of its “100 Best Companies to Work For” for the 18th consecutive year.
To identify the 100 Best Companies to Work For, FORTUNE continued its partnership with the Great Place to Work Institute (GPTWI) to conduct an extensive employee survey of corporate America.
Two-thirds of a company’s score is based on the results of the GPTWI’s Trust Index Survey, which is sent to a random sample of employees from each company. The survey asks questions related to employees’ attitudes about management’s credibility, job satisfaction and camaraderie. The other third is based on responses to the GPTWI’s Culture Audit, which includes detailed questions about pay and benefit programs and a series of open-ended questions regarding hiring practices, methods of internal communication, training, recognition programs and diversity efforts.
On February 16, 2016, Vishva Dixit, Ph.D., Vice President, Physiological Chemistry, received the 2016 Trinity College Dublin Dawson Prize in Genetics for his groundbreaking work on cellular death receptor signaling and inflammation.
The Dawson Prize in Genetics has been awarded approximately every two years since 2006 to a geneticist of international prominence as chosen by the faculty of The Smurfit Institute of Genetics at Trinity College Dublin. Previous recipients of the prize include Nobel laureate Sir John Sulston (2006) and Lasker awardee Mary Claire King (2010). The prize was established by a gift from Dr. George Dawson, founder of the Department of Genetics at Trinity College.
On February 8, 2016, Brian D. Kelley, Vice President, BioProcess, U.S. Biologics Pharma Technical Development, Genentech, was elected into the National Academy of Engineering (NAE) for his leadership in bioprocess technology development and developing cost-effective, robust manufacturing processes for numerous life-saving recombinant protein therapeutics. Election to the NAE is among the highest professional distinctions.
Since 1964, the NAE elects new members annually based on their distinguished and continuing achievements in original research. The NAE is a private, nonprofit institution, which honors those who have made outstanding contributions to engineering research, practice, or education. Members serve as the nation's premier source of independent, expert advice on engineering issues.
In November 2015, Genentech was included on the Human Rights Campaign Foundation’s 2016 Corporate Equality Index (CEI) for the ninth consecutive year. Genentech has received a perfect score of 100 percent each year.
The Corporate Equality Index serves as the gold standard for major U.S. businesses' adoption of inclusive policies, practices and benefits for lesbian, gay, bisexual and transgender employees. A total of 851 businesses were rated in the 2016 CEI with 407 companies achieving the distinction of best places to work for LGBT equality.
In November 2015, FORTUNE magazine named Genentech to its inaugural list of the “50 Best Workplaces For Diversity.”
To identify the 50 Best Workplaces for Diversity, FORTUNE and Great Place to Work Institute partnered with Essence Magazine and People en Español to survey more than 600 companies that have made diversity a top priority.
Two-thirds of a company’s score were based on women and minority employees’ evaluations. The remaining third took into account how well represented women and minorities were within the company’s workforce, management, and executive positions, and how positively they experienced their workplace compared to their colleagues. To be considered companies were required to have at least 30 total employees, of which at least 15 percent were women and 15 percent were racial/ethnic minorities, to be considered for the list.
In November 2015, FORTUNE magazine named Genentech to its inaugural list of the “10 Best Workplaces for Asian Americans.”
To identify the 10 Best Workplaces for Asian Americans, FORTUNE relied on survey data collected from minority employees at more than 600 companies for its 50 Best Workplaces for Diversity survey. To be eligible for the list, each company needed stronger representation of Asian Americans within their organization than exists in the United States workforce overall. Companies that met these criteria were then ranked based on how Asian American employees’ scored their workplace experiences in the survey.
In November 2015, the Silicon Valley Business Journal ranked Genentech No. 12 on its list of the “Top 50 Corporate Philanthropists In Silicon Valley.”
Silicon Valley Business Journal’s Top 50 list recognizes companies who went “above and beyond” to support Silicon Valley’s nonprofit organizations. Based on employee volunteer hours and company charitable contributions, the list honored leading companies who helped nonprofit organizations in Silicon Valley in unique and generous ways.
On November 16, 2015, Frederic de Sauvage, Ph.D., Vice President, Molecular Oncology, was named a Fellow of the American Association for the Advancement of Science (AAAS) in the section of biological sciences for his distinguished contributions to the field of molecular and translational oncology, particularly for advancing targeted therapies for the treatment of basal cell carcinoma.
Since 1874, the AAAS elects Fellows annually to recognize members for their scientifically or socially distinguished efforts to advance science or its applications. The AAAS is the world’s largest scientific society and is dedicated to advancing science for the benefit of all people.
In October 2015, Genentech was named one of the "Top Twenty Employers" in biotechnology and pharmaceuticals by Science Careers – a component of Science magazine produced by the American Association for the Advancement of Science (AAAS). The annual survey of Top Employers polls employees in the biotechnology, biopharmaceutical, pharmaceutical and related industries. This is the fourteenth year Genentech has appeared on the list. We have been ranked the #1 company eight times.
In September 2015, Working Mother magazine named Genentech one of the “100 Best Companies” for working mothers, marking the company’s 22nd appearance on the list. The list ranks companies based on their leave policies, workforce representation, benefits, child care, advancement programs, flexibility policies and more. This year, particular weight was given to representation of women, advancement programs and flexibility.
In July 2015, the San Francisco Business Times ranked Genentech number 12 on its list of "Top Bay Area Corporate Philanthropists" at the annual Bay Area Corporate Philanthropy Summit and Awards. This is the tenth consecutive year the company has appeared on the list.
In May 2015, Genentech received the Allicense Breakthrough M&A Deal of the Year award from Thomson Reuters for its acquisition of Seragon for a portfolio of investigational next-generation selective estrogen receptor degraders (SERDs). The annual Breakthrough award honors creative partnering efforts for top global deals in M&A and Biopharmaceutical Licensing.
Thomson Reuters Recap analysts examined hundreds of biopharma deals negotiated in 2014 and used both subjective and objective criteria to identify the top five most innovative M&A and Licensing deals. The winners were selected by public vote.
On May 1, 2015, Nancy Vitale, vice president, Human Resources and Regional Human Resources Head, North America, and Wendy Young, vice president, Small Molecule Discovery Chemistry, were named by the San Francisco Business Times as "Most Influential Women in Business" in the Bay Area for 2015. Nancy has an exemplary history at Genentech and leads a team of nearly 200 HR professionals across multiple disciplines while serving on the Genentech Executive Committee. Wendy has distinguished herself for her outstanding scientific career presently overseeing an organization of over 100 people within the departments of medicinal, computational, cheminformatics and analytical chemistry.
The San Francisco Business Times honors top women executives at Bay Area corporations and large public, nonprofit and government organizations. The annual list recognizes outstanding women professionals who make a difference in their companies, industries and communities.
Previous winners of this award include Mary Sliwkowski, senior vice president and global head of Pharma Technical Regulatory (2014), Ann Lee-Karlon, senior vice president, Portfolio Management and Operations (2013), Michelle Rohrer, vice president, U.S. Regulatory Affairs (2013), Jennifer Cook, now senior vice president and head of Pharma Region Europe (2012), Sara Kenkare-Mitra, senior vice president and head of Development Sciences (2011), Ann L. Lee, senior vice president and global head of Technical Development (2011), and Sandra Horning, chief medical officer and global head of Product Development (2010).
In March 2015, FORTUNE magazine named Genentech among the "100 Best Companies to Work For" for the 17th consecutive year.
To identify the 100 Best Companies to Work For, each year FORTUNE partners with the Great Place to Work Institute (GPTWI) to conduct an extensive employee survey of corporate America.
Two-thirds of a company's score is based on the results of the GPTWI's Trust Index survey, which is sent to a random sample of employees from each company. The survey asks questions related to employees' attitudes about management's credibility, job satisfaction and camaraderie. The other third is based on responses to the GPTWI's Culture Audit, which includes detailed questions about pay and benefit programs and a series of open-ended questions regarding hiring practices, methods of internal communication, training, recognition programs and diversity efforts.
On January 22, 2015, Bruce Roth, Ph.D., senior vice president, Small Molecule Drug Discovery, was awarded the National Academy of Sciences (NAS) Award for Chemistry in Service to Society. The NAS Award for Chemistry in Service to Society is awarded every two years for contributions to chemistry, either in fundamental science or its application, that clearly satisfy a societal need. Since 1991 the award has recognized the profound benefits of chemistry to society and how advances in chemistry have led to greater economic wealth and a better quality of life. The award is given to chemists working in industry, academia, government, and nonprofit organizations.
In 2015 Minority Engineer Magazine released its “Top 50 Employers” list. We’re proud to be ranked #31. We believe that the best ideas come from having a broad range of perspectives shared by people from all over the world.
The awards are voted on by readers of Minority Engineer, and we’d like to thank them for the honorable mention. We encourage anyone interested in answering the big questions that will face biotech in the coming years to join in the conversation with us.
On December 10th, 2014, Glassdoor released their 7th “Employees’ Choice Awards” and Genentech placed 17 out of 50 “Best Places to Work 2014.” It’s a true honor to know that Genentech employees are so proud of their workplace to take the time to nominate and vote for the award.
Sara Kenkare-Mitra, Ph.D., senior vice president, Development Sciences, Genentech Research and Early Development (gRED), was elected to the Institute of Medicine (IOM) in October 2014. Election to the IOM is considered one of the highest honors in the fields of health and medicine and recognizes individuals who have demonstrated outstanding professional achievement and commitment to service.
Previous elections include Vishva M. Dixit, M.D., vice president, Physiological Chemistry (2012).
In October 2014, Genentech was named one of the “Healthiest Companies to Work For in America” by Greatist.com in the Big Companies (5,000-19,999 employees) category. Greatist.com selected companies with not only exemplary health benefits, but with perks that go above and beyond the norm to help employees live their healthiest lives.
Genentech was also named to the list in 2013.
On October 6, 2014, Sandra Horning, chief medical officer and global head of Product Development, was named one of FierceBiotech’s “Top Women in Biotech” for 2014. Sandra has had a distinguished career as an oncologist, an academic and as a leader at Genentech serving in roles across clinical development, product development and medical affairs.
FierceBiotech honors women each year who have risen to the top ranks within their respective fields in areas including drug development, venture capital and marketing. Sandra was recognized for her leadership in the oncology community and her commitment to developing treatments that make a difference for patients.
In September 2014, Working Mother magazine named Genentech one of the "100 Best Companies" for working mothers, marking the company's 21st appearance on the list. The list ranks companies based on their leave policies, workforce representation, benefits, child care, advancement programs, flexibility practices and more. This year, particular weight was given to representation of women, advancement programs and flexibility.
On September 10, 2014, Anthony P. Adamis, M.D., vice president, Global Head of Ophthalmology, Immunology and Infectious Diseases at Genentech was acknowledged with the prestigious António Champalimaud Vision Award. The award was given to a group of researchers responsible for the development of anti-angiogenic therapy for retinal disease.
The António Champalimaud Vision Award is given for contributions to overall vision research and contributions to the alleviation of visual problems, primarily in developing countries. The work of this year's recipients covers the entire research process, from the identification of the molecule, to the understanding of its role in retinal-vascular disease in animals and humans, to the evaluation of an inhibitor and its final application in the treatment of affected patients.
On August 1, 2014, Michelle Rohrer, vice president of U.S. Regulatory Affairs, was named by PharmaVOICE magazine as one of the 100 most inspiring people in the life sciences industry. Michelle has an exemplary history in the biotech industry and has served in roles across research and development, quality control and regulatory at Genentech.
The annual PharmaVOICE 100 list is selected from submissions provided by industry executives based on how the nominee has inspired and motivated them, their influence as a corporate leader, and their positive impact on the industry. Michelle was recognized for her ability to innovate as well as develop breakthrough strategies.
Previous employees who have received this honor include Jack Phillips, president and CEO of Roche Diagnostics (2012), Carol Wells, senior director, Genentech (2010) and Maryann Szabo, head of site management, director, North American Regional Monitoring Network (2010).
In July 2014, Genentech was awarded the Beyond the Check Community Impact Award by the San Francisco Business Times. The award recognizes companies committed to making the world a better place, not only in day-to-day work, but by enabling employees to support their communities. The award looks beyond monetary donations and focuses on volunteerism and innovation. Genentech was recognized for its efforts to help employees foster deep relationships with the community that result in meaningful change. During Genentech Gives Back Week alone, our employees volunteered over 7,000 hours, serving 47 nonprofits and 154 volunteer projects.
In June 2014, Genentech was ranked as the #6 large company (5000+ employees) on ComputerWorld’s Best Places to Work in IT list. Companies are chosen based on a questionnaire regarding offerings in categories like benefits, workplace diversity, career development, training opportunities and employee retention. ComputerWorld specifically recognized Genentech’s Personal Excellence Program, designed to help employees increase self-awareness and embrace new behaviors, driven by feedback and learning along the way.
In April 2014, the San Francisco Business Times named Genentech #1 on its annual list of the "Best Places to Work in the Bay Area" in the "extra-large companies" category, defined as having over 1,500 employees. This marks the tenth consecutive year that Genentech has appeared on the list. We have been ranked the #1 company four times. The ranking was decided largely on the basis of employee feedback via an online survey.
In December 2013, Bruce Roth, senior vice president, Small Molecule Drug Discovery, was named by Scrip as three of its 100 Leaders in the healthcare industry. Roche’s Daniel O’Day, chief operating officer, Pharmaceuticals Division was also recognized. The Scrip Intelligence editorial team selected leaders based on their strong impact on the transformation of the healthcare industry.
Bruce Roth was recognized for his leadership and contributions in research and development. Daniel O’Day was honored for his leadership in the pharmaceutical industry.
In December 2014, Genentech was included on the Human Rights Campaign Foundation’s 2014 Corporate Equality Index (CEI) for the eighth consecutive year. Genentech has received a perfect score of 100 percent seven times.
The Corporate Equality Index – now in its 13th year – serves as the gold standard for major U.S. businesses' adoption of inclusive policies, practices and benefits for lesbian, gay, bisexual and transgender employees. A total of 934 businesses were rated in the 2014 CEI with a record 303 companies achieving the distinction of best places to work for LGBT equality.
In July 2014, the San Francisco Business Times ranked Genentech number 13 on its list of "Top Bay Area Corporate Philanthropists" at the annual Bay Area Corporate Philanthropy Summit and Awards. This is the ninth consecutive year the company has appeared on the list.
On December 3, 2013, Ian Clark, chief executive officer of Genentech, accepted The Economist Innovation Award on behalf of Genentech in London. The Economist’s panel of 30 international experts selected Genentech for the Corporate Award, recognizing Genentech for its impressive track record in research and scientific innovation.
The Economist Innovation Awards honor corporations and individuals in the fields of bioscience, computing and telecommunications, energy and the environment, social and economic innovation, process and service innovation, consumer products, a flexible “no boundaries” category, and the corporate use of innovation. Genentech joins previous award winners Google (2012) and Amazon (2011).
On October 29, 2013, the American Federation for Aging Research (AFAR) recognized Michael Varney, executive vice president, Genentech Research and Early Development (gRED), and Andrew Chan, senior vice president, Research Biology, for their work to advance the discovery of medicines for age-related diseases such as cancer, neurologic, autoimmune and inflammatory diseases.
AFAR is dedicated to the advancement of innovative research in the field of healthy aging. For more than 30 years, it has supported physicians and scientists specializing in geriatric medicine and research to better understand how people’s bodies change as they age.
On June 3, 2013, Bruce Roth, now senior vice president, Small Molecule Drug Discovery was awarded the 2013 SCI Perkin Medal for his innovation in applied chemistry resulting in outstanding commercial development.
The SCI Perkin Medal is recognized as the highest honor given for outstanding work in applied chemistry in the United States. It commemorates the discovery of the first synthetic dye (the so-called Perkin mauve) by Sir William Henry Perkin in 1856. This discovery was a significant step forward in organic chemistry that led to the birth of a major segment of the chemical industry. The SCI Perkin Medal was first awarded to Sir William at a banquet held by the SCI in New York in 1906. Since then, more than 100 such awards have been given to notable scientists.
Our co-founder, Herb Boyer received the 2007 Perkin Medal for his work on recombinant DNA.
In April 2013, Vishva M. Dixit, M.D., vice president, Physiological Chemistry at Genentech was elected to the Academy in recognition of his distinguished and continuing achievements in original research. Genentech co-founder Herb Boyer was elected to the Academy in 1985. Ira Mellman, vice president of Research Oncology at Genentech has been a member since 2011.
Seven former Genentech employees are also members of the Academy.
In June 2012, FORTUNE magazine ranked Genentech number 63 on its list of "100 Top MBA Employers." The ranking is based on a survey by Universum research firm that asked 5,748 MBA students (2,109 women and 3,621 men) at 79 top business schools nationwide where they'd most like to work. This is the eighth time Genentech has appeared on the list.
On August 23, 2012, Genentech was selected as the "2012 Trailblazer Biotech Company of the Year" by PM360 Magazine. Genentech was selected based on our stellar achievements, and innovative policies and procedures within our company, community and the world arena. This year's award was based on three criteria: Innovation in Marketing and Advertising, Talent Development, and Social Responsibility.
On February 14, 2012, Genentech was named to Fast Company's 2012 "The World's 50 Most Innovative Companies" list for making targeted, genetics-based cancer therapies. According to the magazine, the list is comprised of companies "whose innovations are having an impact across their industries and our culture." Genentech was also ranked number two in the "Biotech Industry" category.
On September 21, 2012, Ian Clark was selected as the San Francisco Business Times 2012 Most Admired CEO in the Public Companies category. The Bay Area's Most Admired CEO Awards recognizes outstanding Bay Area CEOs.
On February 11, 2011, Ian Clark, chief executive officer, Genentech and head of North American Commercial Operations for Roche was named by the Healthcare Businesswomen's Association (HBA) as its 2011 Honorable Mentor. Ian was recognized for "his dedication to enhancing and accelerating the stature and accomplishments of women in healthcare." The HBA created the Honorable Mentor award eleven years ago to recognize one individual each year who demonstrates long-term support of the advancement of women in the healthcare industry, has a personal dedication to developing, mentoring and promoting women in the industry, and who has been supportive of the HBA.
Genentech makes life-saving medicine. People make Genentech what it is. This video offers insights into who these people are and what it means to them to be working at Genentech.